Skip to Content
Biotechnology

Congo aims to stop its Ebola outbreak with an experimental vaccine

For the first time, health officials will use an experimental vaccine in an effort to stop an Ebola outbreak in its early stages. The last outbreak, in Guinea, Liberia, and Sierra Leone in 2014 and 2015, sickened nearly 29,000 people and killed  more than 11,300.

What happened: In its latest count, the World Health Organization (WHO) reported 42 Ebola cases, including 23 deaths, in the Democratic Republic of the Congo between April 4 and May 13.

How the vaccine works: Manufactured by Merck, it uses an animal virus that’s harmless to humans to carry a gene that makes an Ebola protein. No Ebola drug or vaccine, including Merck’s, has been approved yet by a regulatory agency, such as the US Food and Drug Administration.

Vaccine deployment: The WHO confirmed to MIT Technology Review that 4,300 doses of the vaccine arrived in Kinshasa on May 16 (pictured above). The agency said another 4,000 will be sent in the coming days, and more vaccines will be available if needed.

Real-time response: When the vaccine was tested in a clinical trial in West Africa in 2015, it appeared to be 100 percent effective at preventing the disease from spreading further—but at that point the outbreak there was already waning. This time, health officials hope the vaccine will be able to stop the deadly virus in its tracks.  

Deep Dive

Biotechnology

These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

This biotech startup says mice live longer after genetic reprogramming

The result is a widely anticipated landmark for rejuvenation technology.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.